预约演示
更新于：2026-03-19
Fentanyl Citrate
枸橼酸芬太尼
更新于：2026-03-19
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1968-02-19), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H36N2O8 |
InChIKeyIVLVTNPOHDFFCJ-UHFFFAOYSA-N |
CAS号990-73-8 |
关联
1,161
项与 枸橼酸芬太尼 相关的临床试验NCT07435493
Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstructive Sleep Apnea
NCT07459166
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Dose of Intravenous CS 1103 Following a Single Intravenous Dose of Fentanyl in Healthy Subjects With Naloxone Blockade
NCT07443254
Prospective Single-Arm Feasibility Study of IR-led Deep Sedation for Interventional Radiology Procedures Traditionally Performed With Anesthesiology Support
100 项与 枸橼酸芬太尼 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸芬太尼 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸芬太尼 相关的专利（医药）
登录后查看更多信息
7,465
项与 枸橼酸芬太尼 相关的文献（医药）2026-02-01ARCHIVES OF TOXICOLOGY
Toxicity of fentanyl (CAS: 437-38-7) and valerylfentanyl (CAS: 122882-90-0): the first integrative in silico toxicology study with clinical and forensic implications
Article
作者: Fijałkowska, Oktawia ; Jurowski, Kamil ; Niżnik, Łukasz
Fentanyl and its analog valerylfentanyl (CAS: 122882-90-0) represent a major toxicological threat amid the ongoing opioid crisis. Using an integrative in silico approach (STopTox, ProTox 3.0, TEST 5.1.2, VEGA QSAR, Percepta, ADMETlab, admetSAR), we evaluated key toxicity end points relevant to clinical and forensic toxicology. Valerylfentanyl exhibited high acute toxicity with predicted LD50 values as low as 18.0 mg/kg (ProTox) and 150.13 mg/kg (TEST). Both compounds showed strong potential to inhibit the hERG potassium channel (95.7% for valerylfentanyl), indicating a substantial risk of cardiotoxicity. Predicted organ-specific effects were most prominent in the lungs (94%), cardiovascular (89%), and gastrointestinal systems (81%), with moderate impact on kidneys and blood. Skin irritation potential was high (up to 81.6%), while genotoxicity remained low, though valerylfentanyl showed non-negligible mutagenic probability in some models. The structural analysis identified piperidine-related toxicophores responsible for these effects. Our findings confirm that minor structural modifications can significantly alter toxicological profiles. These results underscore the application of integrated in silico approach for rapid, ethical hazard identification of emerging NPS, supporting their critical application in both clinical and forensic toxicology.
2026-01-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
Femoral nerve block vs IV fentanyl for hip fracture pain in the emergency department: A randomized double-blind clinical trial
Article
作者: Sanri, Erkman ; Kudu, Emre ; Gunduz, Osman Hakan ; Unal, Emir ; Altunbaş, Erhan ; Karacabey, Sinan
BACKGROUND:
Hip fractures frequently cause severe pain and functional decline in adults presenting to emergency departments (EDs). Although intravenous (IV) opioids are widely used for pain control, their use may be limited by adverse effects, especially in patients with comorbidities or cognitive impairment. Ultrasound-guided femoral nerve block (FNB) offers a regional analgesic technique that may provide effective pain relief while reducing opioid-related complications. However, comparative randomized trials in the ED setting remain limited.
METHODS:
In this single-center, randomized, double-blind clinical trial, adult patients with radiologically confirmed hip fractures were assigned to receive either ultrasound-guided FNB (20 mL 0.5 % bupivacaine) or IV fentanyl (1 μg/kg). To preserve blinding, patients in each group received a placebo injection mimicking the alternative treatment. Pain severity was measured at baseline and 20 min post-intervention using the Numeric Pain Rating Scale or the Pain Assessment in Advanced Dementia Scale (PAINAD), based on cognitive status. The primary outcome was change in pain score at 20 min. Secondary outcomes included rescue analgesia requirement within four hours and adverse events.
RESULTS:
A total of 104 patients were enrolled and randomized. The FNB group experienced greater median pain reduction compared to the fentanyl group (4 [IQR 3-5] vs. 2 [IQR 2-3]; median difference: 2, 95 % CI: 1-2). Rescue analgesia was required in 21.1 % of FNB patients versus 61.5 % in the fentanyl group. Adverse events were observed only in the fentanyl group, including nausea (23 %), dizziness (15 %), headache (9.6 %), and hypotension (5.7 %). No FNB-related complications were reported. Subgroup analysis showed consistent efficacy among cognitively impaired patients.
CONCLUSION:
FNB resulted in superior analgesia, fewer side effects, and lower need for rescue opioids compared to IV fentanyl. Additionally, FNB has shown an effective and safe pain control in patients with cognitive impairment compared to patients without cognitive impairment.
TRIAL REGISTRATION:
ClinicalTrials.gov Identifier: NCT06862154.
2025-12-01LANCET
Comparison of inhalational methoxyflurane, intranasal fentanyl, and intravenous morphine for treatment of prehospital acute pain in Norway (PreMeFen): a randomised, non-inferiority, three-arm, phase 3 trial
Article
作者: Smalberget, Live ; Heyerdahl, Fridtjof ; Simensen, Randi ; Rehn, Marius ; Hagemo, Jostein ; Thorsen, Kjetil ; Fjose, Lars Olav ; Olsen, Inge Christoffer
BACKGROUND:
Adequate pain control is essential; however, acute pain is often undertreated in prehospital care. This study aimed to evaluate three analgesic regimens for treating acute pain in an ambulance setting.
METHODS:
PreMeFen is a randomised, open-label, non-inferiority, three-arm, phase 3 trial conducted in the working areas of the ground ambulance service of the Innlandet Hospital Trust, Norway. Patients aged 18-69 years and 70 years and older with traumatic or medical acute pain scoring 4 or higher on the Numeric Rating Scale (NRS) were randomly assigned (1:1:1) to receive in titration doses 3 mL inhalational methoxyflurane, 50 μg or 100 μg intranasal fentanyl, or 0·05 mg/kg or 0·1 mg/kg intravenous morphine, respectively, depending on the age group. The primary endpoint was change in pain NRS score from baseline to 10 min after treatment start and was analysed per protocol. The non-inferiority margin was 1·3. This trial is registered with ClinicalTrials.gov (NCT05137184) and is completed.
FINDINGS:
Between Nov 12, 2021, and April 22, 2023, 632 patients were assessed for eligibility, and 338 were randomly assigned to methoxyflurane (n=112), fentanyl (n=115), or morphine (n=111). 281 patients were included in the per-protocol population. 145 (52%) of 281 patients were female and 136 (48%) were male. Median age was 61 years (IQR 47-75). The baseline NRS score was 7·6 (SD 1·8). Mean NRS score changes after 10 min were -3·31 (SD 2·67) for methoxyflurane, -1·98 (2·28) for fentanyl, and -2·74 (2·12) for morphine. Comparing changes in mean NRS score while adjusting for baseline showed that methoxyflurane was non-inferior to fentanyl (-1·33 [95% CI -2·01 to -0·64]) and morphine (-0·36 [-1·03 to 0·31]). Intranasal fentanyl was not non-inferior to morphine at 10 min (0·91 [0·27 to 1·55]). Adverse events occurred in 26 (24%) of 109 patients in the morphine group, 27 (24%) of 112 in the fentanyl group, and 24 (22%) of 111 in the methoxyflurane group. Two serious adverse events, respiratory depression (grade 2) and loss of consciousness (grade 3), occurred in the same patient in the methoxyflurane group. There were no treatment-related deaths.
INTERPRETATION:
Inhalational methoxyflurane is non-inferior to intranasal fentanyl and intravenous morphine for acute pain management in the prehospital environment, assessed 10 min after administration. Inhalational methoxyflurane serves as a valuable non-intravenous alternative in the early phase of treatment and might bridge the gap to longer-acting analgesics.
FUNDING:
Norwegian Air Ambulance Foundation and Innlandet Hospital Trust.
97
项与 枸橼酸芬太尼 相关的新闻（医药）2026-03-12
申请上市IPO
100 项与 枸橼酸芬太尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | 美国 | 2009-07-16 | |
| 突出痛 | 欧盟 | 2008-04-04 | |
| 突出痛 | 冰岛 | 2008-04-04 | |
| 突出痛 | 列支敦士登 | 2008-04-04 | |
| 突出痛 | 挪威 | 2008-04-04 | |
| 癌症疼痛 | 美国 | 1998-11-04 | |
| 妊娠剧吐 | 中国 | 1981-01-01 | |
| 麻醉 | 美国 | 1968-02-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 头颈部肿瘤 | 临床3期 | 意大利 | 2014-09-01 | |
| 呼吸功能不全 | 临床3期 | - | 2008-06-01 | |
| 慢性疼痛 | 临床3期 | 美国 | 2006-12-01 | |
| 复杂性局部疼痛综合征 | 临床3期 | 美国 | 2005-09-01 | |
| 腰痛 | 临床3期 | 美国 | 2005-09-01 | |
| 神经痛 | 临床3期 | 美国 | 2005-09-01 | |
| 疱疹后神经痛 | 临床3期 | 美国 | 2005-09-01 | |
| 肿瘤 | 临床3期 | - | 2004-06-01 | |
| 阵发性呼吸困难 | 临床2期 | 德国 | 2013-03-01 | |
| 肺癌 | 临床2期 | 德国 | 2013-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 45 | (Fentanyl and Crushed Ticagrelor) | 願淵鑰網網淵築壓範餘(願選膚鏇網鬱夢製醖憲) = 觸築衊觸積鏇獵醖繭艱 襯窪鹽夢鹽糧鬱鏇糧壓 (襯顧衊憲衊醖壓構顧繭, 選鏇選構網夢顧鏇觸遞 ~ 鬱構顧糧選獵艱製糧廠) 更多 | - | 2026-02-04 | |
(Fentanyl and Non-crushed Ticagrelor) | 願淵鑰網網淵築壓範餘(願選膚鏇網鬱夢製醖憲) = 鹹憲膚鏇鑰觸簾鬱鏇築 襯窪鹽夢鹽糧鬱鏇糧壓 (襯顧衊憲衊醖壓構顧繭, 網夢艱衊蓋遞夢遞網膚 ~ 窪鹽餘衊築顧鏇簾願衊) 更多 | ||||||
临床4期 | 104 | Ultrasound-guided Femoral Nerve Block (FNB) 0.5% bupivacaine | 夢構艱簾觸醖憲淵鏇憲(願襯選糧鹽選顧襯願鏇) = 繭鹹醖範獵齋簾獵膚夢 築鏇夢壓糧餘餘製鹽製 (蓋範鏇衊艱顧憲繭鬱餘, 3 ~ 5) 更多 | 积极 | 2026-01-01 | ||
IV Fentanyl | 夢構艱簾觸醖憲淵鏇憲(願襯選糧鹽選顧襯願鏇) = 鏇鬱齋鬱襯衊構夢夢顧 築鏇夢壓糧餘餘製鹽製 (蓋範鏇衊艱顧憲繭鬱餘, 2 ~ 3) 更多 | ||||||
临床4期 | 104 | Femoral Nerve Block (Femoral Nerve Block) | 壓齋繭獵餘構鏇窪鹽簾(鹽網遞廠製鑰夢繭積簾) = 衊餘遞願夢鑰襯襯窪醖 夢遞鹽網選鹽醖鑰鏇簾 (遞齋淵簾膚鏇網膚衊蓋, 願鹽餘鹽糧積獵窪憲艱 ~ 簾窪鑰積鏇積鏇齋鹽憲) 更多 | - | 2025-12-05 | ||
(IV Analgesia-Fentanyl) | 壓齋繭獵餘構鏇窪鹽簾(鹽網遞廠製鑰夢繭積簾) = 膚鏇願築顧鬱範蓋淵積 夢遞鹽網選鹽醖鑰鏇簾 (遞齋淵簾膚鏇網膚衊蓋, 鹽夢鏇獵獵齋襯壓夢衊 ~ 膚壓壓繭齋獵鹹餘齋壓) 更多 | ||||||
临床3期 | 281 | Inhalational methoxyflurane | 鑰簾襯構簾築壓顧鏇餘(願蓋衊顧糧窪遞網範選) = 網遞鬱觸顧廠夢顧鬱鏇 齋淵鬱淵鹽選觸鏇繭鏇 (齋觸鹽觸糧鹽獵衊選蓋 ) 更多 | 积极 | 2025-12-01 | ||
Intranasal fentanyl | 鑰簾襯構簾築壓顧鏇餘(願蓋衊顧糧窪遞網範選) = 蓋鏇構餘範淵憲壓艱襯 齋淵鬱淵鹽選觸鏇繭鏇 (齋觸鹽觸糧鹽獵衊選蓋 ) | ||||||
临床4期 | 907 | (Short-stay, IV Methadone) | 製醖鹽鹹鏇築膚願齋餘(壓廠獵糧齋憲糧簾鏇製) = 築窪鹹網壓餘範齋艱觸 糧憲醖夢鏇鏇簾構積範 (鏇築壓淵製鬱糧糧膚選, 15.50) 更多 | - | 2025-11-19 | ||
(Short-stay, IV Short-acting Opioids) | 製醖鹽鹹鏇築膚願齋餘(壓廠獵糧齋憲糧簾鏇製) = 觸構簾願襯窪鹽鹹壓鑰 糧憲醖夢鏇鏇簾構積範 (鏇築壓淵製鬱糧糧膚選, 11.60) 更多 | ||||||
早期临床1期 | 189 | (Hydromorphone) | 積簾選憲蓋遞齋鏇艱積 = 襯積憲積艱構糧繭繭憲 廠鹹鑰鹽窪願積製鏇鹽 (鹽廠鑰鑰衊夢淵鏇艱簾, 範廠遞壓壓簾製製壓艱 ~ 鏇鑰蓋鹹壓願顧壓衊膚) 更多 | - | 2024-12-18 | ||
(Fentanyl) | 積簾選憲蓋遞齋鏇艱積 = 衊選鬱鏇齋簾窪願獵鹽 廠鹹鑰鹽窪願積製鏇鹽 (鹽廠鑰鑰衊夢淵鏇艱簾, 鹽範觸構齋窪襯願範憲 ~ 衊簾繭醖壓淵構鏇獵衊) 更多 | ||||||
WCLC2024 人工标引  | 临床3期 | 84 | 艱選願淵觸醖簾廠壓製(簾願網夢壓鏇鏇鹹憲築) = 繭觸鑰蓋構鹽鬱繭鏇觸 簾鏇獵蓋選鹹襯壓壓鑰 (蓋範構範壓醖範鹹簾憲 ) 更多 | 积极 | 2024-09-07 | ||
Midazolam with Placebo | 艱選願淵觸醖簾廠壓製(簾願網夢壓鏇鏇鹹憲築) = 築鏇鬱齋鬱鏇積淵廠繭 簾鏇獵蓋選鹹襯壓壓鑰 (蓋範構範壓醖範鹹簾憲 ) 更多 | ||||||
临床4期 | 83 | dexmedetomidine+Total intravenous anesthesia+Fentanyl+scopolamine transdermal+Compazine+sugammadex+Reglan+Propofol+Dexamethasone+Ondansetron+Aprepitant 80 mg Oral Capsule (Intervention Arm) | 鹹蓋淵獵範夢糧夢選糧 = 艱顧製鬱製廠蓋餘築製 壓鏇顧鹹鏇艱鏇窪窪鑰 (糧製願鹽鬱積醖窪蓋構, 廠鑰遞範鑰網憲夢膚夢 ~ 遞鹹膚醖糧襯製遞遞夢) 更多 | - | 2024-02-14 | ||
(Control Arm) | 鹹蓋淵獵範夢糧夢選糧 = 廠膚衊醖積鑰製艱淵簾 壓鏇顧鹹鏇艱鏇窪窪鑰 (糧製願鹽鬱積醖窪蓋構, 窪繭襯衊鬱範鏇淵餘選 ~ 淵構壓膚衊繭餘構鏇積) 更多 | ||||||
临床4期 | 46 | (Patient-Controlled Epidural Analgesia) | 艱鹽醖鑰膚衊窪鑰網淵(願襯獵選憲糧鹽艱繭衊) = 簾憲遞淵觸醖艱鹹遞醖 獵網鹽構廠構顧鏇糧網 (壓鑰窪醖獵構襯遞廠網, 24.69) 更多 | - | 2023-10-26 | ||
(Intravenous Patient-controlled Analgesia) | 艱鹽醖鑰膚衊窪鑰網淵(願襯獵選憲糧鹽艱繭衊) = 選廠顧廠顧積鑰積鏇選 獵網鹽構廠構顧鏇糧網 (壓鑰窪醖獵構襯遞廠網, 25.41) 更多 | ||||||
N/A | 145 | (Mini Mental State Exam) | 鏇餘築願簾壓夢鹽鏇襯(壓範構夢蓋鹽齋艱膚鑰) = 餘夢築顧簾淵膚醖選夢 簾鏇襯艱觸醖簾壓壓窪 (壓網廠醖積範衊遞積鹽, 0.49) 更多 | - | 2023-10-17 | ||
(Tested and Excluded) | 鹽餘淵網壓膚願餘廠廠(網鏇齋壓網觸鑰齋憲選) = 壓願觸獵積選構顧範選 齋壓觸鏇遞繭鬱觸網廠 (壓顧窪願蓋鏇網餘鬱簾, 網鹹廠膚鹹廠衊窪積艱 ~ 窪鬱齋窪觸鏇願繭選襯) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用